1. Home
  2. KRYS vs CYTK Comparison

KRYS vs CYTK Comparison

Compare KRYS & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Krystal Biotech Inc.

KRYS

Krystal Biotech Inc.

HOLD

Current Price

$262.33

Market Cap

7.8B

Sector

Health Care

ML Signal

HOLD

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

HOLD

Current Price

$65.30

Market Cap

7.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KRYS
CYTK
Founded
2015
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.8B
7.6B
IPO Year
2017
2004

Fundamental Metrics

Financial Performance
Metric
KRYS
CYTK
Price
$262.33
$65.30
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
11
18
Target Price
$297.60
$88.94
AVG Volume (30 Days)
217.1K
1.9M
Earning Date
05-05-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
128.00
N/A
EPS
6.84
N/A
Revenue
$389,130,000.00
$13,368,000.00
Revenue This Year
$39.88
$6.88
Revenue Next Year
$34.38
$308.26
P/E Ratio
$38.23
N/A
Revenue Growth
33.94
N/A
52 Week Low
$123.03
$29.31
52 Week High
$298.30
$70.98

Technical Indicators

Market Signals
Indicator
KRYS
CYTK
Relative Strength Index (RSI) 55.55 55.76
Support Level $251.93 $59.12
Resistance Level $293.60 $69.67
Average True Range (ATR) 9.28 2.41
MACD 2.05 0.51
Stochastic Oscillator 90.05 64.57

Price Performance

Historical Comparison
KRYS
CYTK

About KRYS Krystal Biotech Inc.

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: